Topiramate and its clinical applications in epilepsy
- 24 March 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (6), 811-823
- https://doi.org/10.1517/14656566.7.6.811
Abstract
Topiramate, a derivative of the monosaccharide d-fructose, has shown a wide spectrum of antiepileptic efficacy in both animal models and clinical trials. Multiple putative mechanisms of action include voltage-sensitive sodium channel blockade, calcium channel inhibition, increase of potassium conductance, GABA-mediated chloride current increment, glutamate-mediated neurotransmission inhibition and carbonic anhydrase isoenzyme inhibition. In general, the clinical response is maintained in the long-term. The most common side effects include somnolence, fatigue, headache, psychomotor slowing, confusion, difficulty with memory, impaired concentration and attention, speech and language problems and weight loss. If slowly titrated and used at a low-to-medium dosage, it is well tolerated and offers a valid therapeutic option, the relevance of which is comparable to that of the most widely used 'old' antiepileptic drugs. As it is not yet wholly clear which specific epilepsy syndromes may benefit most from topiramate with respect to other drugs, more accurate indications for initial monotherapy would require syndrome-oriented trials and more clinical experience.Keywords
This publication has 97 references indexed in Scilit:
- Diagnosing and predicting refractory epilepsyActa Neurologica Scandinavica, 2005
- EURAP: An International Registry of Antiepileptic Drugs and PregnancyEpilepsia, 2004
- North American Antiepileptic Drug Pregnancy RegistryEpilepsia, 2004
- Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled TrialEpilepsia, 2000
- Topiramate as Add‐On Therapy: Pooled Analysis of Randomized Controlled Trials in AdultsEpilepsia, 2000
- Comparison of the Steady‐State Pharmacokinetics of Topiramate and Valproate in Patients with Epilepsy During Monotherapy and Concomitant TherapyEpilepsia, 1997
- Topiramate Monotherapy for Partial Onset SeizuresEpilepsia, 1997
- Double‐Blind, Placebo‐Controlled Trial of Topiramate (600 mg Daily) for the Treatment of Refractory Partial EpilepsyEpilepsia, 1996
- Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial SeizuresEpilepsia, 1996
- Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neuronsNature, 1990